Mumbai-based pharma major, Lupin Ltd, has reported a staggering 73 per cent year-on-year increase in its consolidated profit in the September quarter as its sales grow in the US and other emerging markets.
The company reported a consolidated profit after tax of ₹1,485 crore in Q2, as against a profit after tax (PAT) of ₹859 crore for the July-September quarter of the last fiscal.
Sales rose to ₹6,831 crore for the second quarter compared with ₹5,497 crore in the year-ago period, the firm said in a statement, adding that its US sales rose to ₹2,762 crore during the second quarter, up 47 per cent as compared with ₹1,875 crore in the year-ago period.
“We continue to see robust growth in revenues and EBITDA led by strong performance across the board, in the US, emerging markets, other developed markets and in India, supported by higher operational efficiencies and sustained investments. We intend to leverage the performance of H1 to deliver a strong FY26,” said Lupin Managing Director, Nilesh Gupta.
Also Read: Indian pharma drug for mental health disorder gets USFDA nod
Meanwhile, Lupin Ltd’s India sales stood at ₹2,078 crore in the September quarter, against ₹2,009 crore in the year-ago period.
Emerging market sales rose to ₹923 crore in the September quarter, up 45 per cent as compared to ₹635 crore in the same period of the last fiscal.
Shares of the drug firm ended 2.11 per cent down at ₹1,956.05 apiece on the BSE.
Follow us
